Key Compliance Aspects of Article 19 in EU Market Regulation

Note on figures cited below. Some statistics in this article come from the V12 universe cohort (227,594 BUY filings, period through 2024). Since 2025-01-01 the live out-of-sample BUY universe (28 markets) shows a 52.96 percent win rate and a +8.59 percent mean 90-day return on 20,688 filings. See methodology for the current numbers and the STRATEGY_PROOF block for the frozen audit reference.

One missed filing can turn a routine share sale into a regulatory problem with a three-day fuse.

Regulatory writing often manages the rare feat of being both short and easy to misread. Article 19 of the EU Market Abuse Regulation, usually called MAR Article 19, is a good specimen. It looks like a disclosure rule for directors dealing in their own stock. It is that, but also more specific, more mechanical, and more unforgiving than many executives assume.

This matters because the rule sits at the junction of governance, market transparency and personal liability. A chief executive who sells shares to pay tax on a vesting event, a non-executive director whose spouse trades, or a finance director who exercises options during a closed period can all find themselves inside Article 19 territory. The paperwork is not optional, the clock is short, and national regulators have shown little appetite for "we thought HR had handled it" as a defence.

The European framework is harmonised at a high level, but local practice still matters. France is a useful case study because the Autorité des marchés financiers, the AMF, has published practical guidance and enforces MAR in a market with a large population of listed issuers. ESMA, for its part, supplies the technical standards and Q&A that make the rule operable rather than merely aspirational.

What Article 19 is trying to do

Article 19 is built on a plain market logic. If senior insiders are buying or selling securities linked to their own issuer, outside investors may want to know. Sometimes that information is useful because insiders know the business well. Sometimes it is useful because the transaction is routine and tells the market very little. MAR does not ask the market to guess which is which in advance. It requires disclosure so the market can decide.

The rule therefore focuses on who is trading and what they are trading, rather than on whether the trade looks suspicious. That is a key distinction. Article 19 is not the insider dealing prohibition. A transaction can be perfectly lawful on the merits and still be reportable under Article 19. Conversely, filing an Article 19 notice does not cleanse a trade that was executed while in possession of inside information.

The two audiences: regulator and market

The rule creates a dual reporting chain:

1. The PDMR, or a closely associated person, notifies the issuer and the national competent authority.
2. The issuer then makes the information public promptly, and no later than three business days after the transaction.

That architecture explains why compliance failures tend to be operational rather than conceptual. The legal test is often straightforward. The missed deadline usually comes from uncertainty over who owns the process, whether the threshold has been crossed, and whether a transaction by a spouse or family trust was picked up in time.

Why the details matter

The details matter because Article 19 is highly technical in three places:

• the scope of PDMRs and closely associated persons,
• the annual threshold calculation,
• the interaction between disclosure and the 30-day closed period.

Most mistakes are made in one of those three.

Who must disclose, and whose trades count

The first question is not whether someone is an insider in the colloquial sense. It is whether they are a person discharging managerial responsibilities, or PDMR, for the issuer.

PDMRs: the formal definition

Under MAR, a PDMR is broadly either:

• a member of the administrative, management or supervisory body of the issuer, or
• a senior executive who is not on the board but has regular access to inside information relating directly or indirectly to the issuer and power to take managerial decisions affecting the issuer's future developments and business prospects.

The first limb catches directors and supervisory board members. The second limb catches certain senior executives, often the CFO, COO, heads of major divisions, and occasionally others depending on governance structure. It is a functional test, not a vanity-title test. Calling someone "senior adviser" does not help if they in fact sit in the room where material decisions are made.

For issuers, this means maintaining an accurate PDMR list is not a clerical afterthought. It is the foundation of Article 19 compliance.

Closely associated persons: where surprises usually begin

Article 19 does not stop with the PDMR. It also covers persons closely associated with a PDMR, often abbreviated as CAPs or PCAs in local practice. These include:

• a spouse or partner considered equivalent to a spouse under national law,
• dependent children,
• relatives who have shared the same household for at least one year on the date of the transaction,
• legal persons, trusts or partnerships whose managerial responsibilities are discharged by the PDMR or by a closely associated person, or which are directly or indirectly controlled by them, or set up for their benefit, or whose economic interests are substantially equivalent to theirs.

This is where many otherwise careful insiders lose the plot. The CFO may know not to trade during a closed period. The family investment vehicle may not. The director may understand the notification form. The spouse's broker certainly does not. MAR nevertheless treats these transactions as reportable because the market effect is similar.

What instruments are covered

Article 19 is not limited to ordinary shares. It extends to:

• shares,
• debt instruments,
• derivatives or other financial instruments linked to them,
• related instruments of the issuer or of an associated issuer in some cases.

The delegated regulation and ESMA guidance make clear that reportable transactions include a wide range of events: acquisitions, disposals, subscriptions, exchanges, pledges, lending, gifts, inheritances in some circumstances, option exercises, and transactions carried out under life insurance policies where the investment risk is borne by the policyholder and they have power to make investment decisions.

That breadth is intentional. If the instrument changes the economic exposure of the PDMR or closely associated person to the issuer, assume Article 19 may be interested.

Employee plans are not a safe harbour from disclosure

A common misunderstanding is that equity compensation events are "internal" and therefore outside the rule. They are not. Grants, vestings, exercises, sales to cover taxes, and transfers into or out of plan structures can all be in scope depending on the facts and the implementing standards.

The practical lesson is dull but useful: HR, legal, company secretariat and the broker administering the plan must all be aligned on reporting triggers. Dull systems work. Heroic memory does not.

The threshold, and why "EUR 5,000" is only the beginning

The phrase most often quoted from Article 19 is "EUR 5,000". It is also the phrase most often quoted incompletely.

Default threshold versus national option

Article 19(8) sets the threshold at EUR 5,000 within a calendar year. However, national competent authorities may decide to increase that threshold to EUR 20,000 and must inform ESMA of that decision. France has done so. For issuers under AMF supervision, the practical threshold is therefore EUR 20,000, not EUR 5,000.

That is not a drafting curiosity. It changes the filing burden materially for lower-value transactions, especially under employee share plans.

How the threshold is calculated

The threshold is calculated by aggregating all transactions carried out for the account of the PDMR or closely associated person in the relevant calendar year. Several points matter:

• It is cumulative, not per trade.
• It is calculated without netting. A buy and a sell do not cancel each other out.
• Once the threshold is reached, all subsequent transactions in that year must be notified.
• The calculation is generally done per person, per issuer.

This last point deserves attention. The threshold is not a group family allowance. The PDMR has a threshold. The spouse has a threshold. A controlled legal entity may have its own analysis, depending on how the transactions are attributed and reported. The issuer should not guess. It should document the approach and apply it consistently.

A simple example

Suppose a French-listed issuer is supervised by the AMF, so the threshold is EUR 20,000.

• In February, a director buys EUR 8,000 of shares. No filing yet, assuming no earlier in-scope trades that year.
• In May, the same director exercises options and receives shares worth EUR 9,000. Aggregate is now EUR 17,000. Still below threshold.
• In July, the director sells EUR 5,000 of shares to cover tax. Aggregate reaches EUR 22,000. The threshold has been crossed.
• The July transaction must be notified within three business days.
• Any later in-scope transaction in that calendar year must also be notified, even if individually small.

The market often finds this rule mildly absurd when a tiny fourth-quarter transaction must be disclosed because of a threshold crossed months earlier. MAR is not especially concerned with aesthetic coherence.

Why issuers should still monitor below-threshold activity

Even where no filing is yet required, issuers should ask PDMRs and closely associated persons to pre-clear and log in-scope transactions from the start of the year. Otherwise the company learns about the threshold crossing only after it has already missed the deadline.

That is the operational point hidden inside the legal rule. You cannot comply with a cumulative threshold if you only collect information once the threshold has been crossed.

The T+3 deadline, and the issuer's role in publication

The deadline is short enough to punish hesitation and long enough to create false confidence. Article 19 requires notification within three business days of the transaction.

Who files what, and when

The PDMR or closely associated person must notify:

• the issuer, and
• the competent authority.

The issuer must then ensure the information is made public promptly and no later than three business days after the transaction.

In practice, many issuers in France and elsewhere facilitate or coordinate the filing. Some prepare the standard form for the insider to sign or submit. That is sensible, but it does not transfer the legal obligation away from the PDMR or closely associated person. Shared process is not shared liability.

What counts as the transaction date

The relevant date is generally the date on which the transaction is executed, not the settlement date. For market trades, that is usually straightforward. For employee plans, option exercises, gifts, or transactions under managed arrangements, the correct date can be less obvious. ESMA's implementing standards and Q&A are the place to check, not office folklore.

The standardised form is not optional decoration

Commission Implementing Regulation (EU) 2016/523 sets out the standard form and template for notifications under Article 19. The form requires details such as:

• the name of the person,
• the reason for the notification,
• the name of the issuer,
• a description and identifier of the financial instrument,
• the nature of the transaction,
• the date and place of the transaction,
• the price and volume.

This standardisation is useful because it makes public disclosures comparable. It is also useful because incomplete forms are one of the easiest ways to turn a timely filing into a defective one.

Business days means business days, not "when everyone is back from the off-site"

The phrase "three business days" sounds forgiving until a trade is executed on a Thursday before a public holiday. Issuers should therefore define:

• who receives notifications,
• how they are escalated,
• what happens during holidays,
• who has authority to approve publication,
• how evidence of submission is retained.

Most Article 19 failures are not legal mysteries. They are workflow failures in respectable clothing.

Closed periods: disclosure is not permission

Article 19 contains a second rule that is often confused with the first. Separate from the disclosure obligation, a PDMR must not conduct transactions on their own account or for the account of a third party, directly or indirectly, during a closed period of 30 calendar days before the announcement of an interim financial report or a year-end report which the issuer is obliged to make public.

The closed period rule in plain English

If you are a PDMR, the default position is simple: do not trade in the 30 days before results. If you do trade, there had better be a valid exception and proper internal approval.

This is not merely a best-practice blackout policy. It is a MAR prohibition, although issuers often overlay stricter internal dealing codes.

Exceptions are narrow

MAR permits the issuer to allow trading during a closed period in limited circumstances, notably:

• exceptional circumstances, such as severe financial difficulty requiring the immediate sale of shares, or
• transactions made under, or related to, employee share or saving schemes, qualification or entitlement of shares, or transactions where the beneficial interest in the relevant security does not change, subject to conditions and issuer assessment.

The delegated regulation, particularly Commission Delegated Regulation (EU) 2016/522, adds detail on what may count as exceptional circumstances and on the types of transactions that may be permitted. "I had planned to diversify" is not exceptional. "I need liquidity to meet a legally enforceable financial commitment that cannot reasonably be met otherwise" is closer to the intended category.

Disclosure still applies if an exception permits the trade

This is where people conflate two separate questions:

1. May the PDMR trade at all during the closed period?
2. If the trade occurs, must it be disclosed under Article 19?

A permitted trade during a closed period can still be reportable. Approval to trade is not a waiver of disclosure. Compliance teams should treat the two analyses separately and document both.

AMF practice makes process discipline visible

The AMF's public materials on managers' transactions and issuer obligations repeatedly stress timely reporting and the importance of robust internal procedures. The French market's practical lesson is not exotic. Keep a current PDMR list, identify closely associated persons, require pre-clearance, monitor thresholds, and centralise filing responsibility. The law is European. The embarrassment is local.

Sanctions, enforcement and the cost of getting casual

Article 19 is not a ceremonial filing rule. National regulators can investigate failures to notify, late notifications, incomplete disclosures, and breaches of the closed-period restriction. Sanctions vary by jurisdiction but can include administrative fines, public censure, and, in serious cases involving related misconduct, broader enforcement consequences.

What regulators care about

Regulators usually care about three things:

• whether the market received the information on time,
• whether the issuer had adequate systems and controls,
• whether the individual understood and complied with their obligations.

A single late filing may be treated differently from a pattern of weak controls. But repeated "administrative oversights" tend to attract scepticism. They should.

The issuer's exposure is real even though the insider files

Because the issuer must make the information public within the same outer deadline, the company cannot shrug and say the executive forgot to tell us. From the regulator's perspective, that answer often confirms the control weakness rather than curing it.

That is why well-run issuers usually implement a dealing code that goes beyond the bare MAR text. Typical features include:

• mandatory pre-clearance for all PDMR and CAP transactions,
• annual written acknowledgments,
• onboarding notices to spouses and family vehicles,
• broker instructions for employee plans,
• a central register of in-scope transactions,
• holiday cover for filings,
• periodic training.

None of this is glamorous. Neither is enforcement correspondence.

Common failure modes

Across markets, the same errors recur:

Misidentifying who is a PDMR

Companies often under-scope senior executives who regularly access inside information and influence business decisions. If the role walks like a PDMR and talks like a PDMR, the title will not save it.

Forgetting closely associated persons

Spouses, dependent children and controlled entities are the classic source of surprise filings. The surprise is usually avoidable.

Treating the threshold as per transaction

It is cumulative over the calendar year, without netting. This point should be printed in large type and placed near every equity-plan administrator.

Confusing trade date and settlement date

The clock generally starts on execution, not settlement.

Assuming internal approval solves everything

It does not. Closed-period approval, where available, is separate from disclosure, and neither overrides the ban on trading while in possession of inside information.

A dry but useful compliance checklist

For issuers supervised by the AMF or another EU competent authority, a sensible Article 19 framework usually includes:

1. A documented PDMR identification process.
2. Written notices to PDMRs of their obligations under Article 19.
3. A process for PDMRs to notify closely associated persons in writing.
4. A central log of all in-scope transactions, including below-threshold transactions.
5. A standard form pack using the implementing regulation template.
6. A pre-clearance policy covering closed periods and ad hoc blackouts.
7. A publication workflow that can operate within T+3 even during holidays.
8. Record retention for submissions, approvals and disclosures.

That checklist is not exciting. It is, however, much cheaper than reconstructing who knew what on day four.

How to read Article 19 without over-reading it

The temptation with insider transaction rules is to infer too much from the disclosure. Investors often read a director purchase as bullish and a sale as ominous. Sometimes they are right. Sometimes the sale funds tax, divorce, school fees or a portfolio rebalance. MAR does not certify motive. It standardises visibility.

What Article 19 tells the market

It tells the market that a defined insider, or someone close to them, changed economic exposure to the issuer through a reportable transaction. That is useful information. It is not a valuation model.

What Article 19 does not tell the market

It does not tell the market:

• whether the person had a positive or negative view of fundamentals,
• whether the transaction was discretionary or automatic,
• whether the trade was large relative to the person's overall holdings unless you do the extra work,
• whether the transaction occurred under a plan, tax obligation, or legal necessity.

That is why serious analysis of insider transactions usually combines Article 19 disclosures with context: prior holdings, compensation structure, timing around results, and whether multiple insiders are acting in the same direction.

The legal takeaway for insiders

For insiders themselves, the reading is simpler. If you are a PDMR, or connected to one, Article 19 is not a theory exam. It is a process rule. Ask four questions before acting:

1. Am I, or is the account owner, a PDMR or closely associated person?
2. Is the instrument in scope?
3. Has the annual threshold been reached, taking prior transactions into account?
4. Are we in a closed period, and if so, is there a valid exception and documented clearance?

If any answer is uncertain, the correct next step is not to trade first and tidy up later. Markets have many opportunities. Filing windows have fewer.

The practical burden of Article 19 is modest for firms that build a proper control framework and irritating for firms that rely on memory, spreadsheets and optimism. Regulation has a way of punishing optimism.

The concrete next step for any EU-listed issuer is straightforward: review the current PDMR list, re-notify closely associated person obligations, and test whether your filing workflow can actually produce a complete Article 19 notification and public release inside T+3 during a holiday week. The open question is not whether the rule is clear enough in principle. It is whether your process still works when the trade arrives at 5:40 pm on the day before results season begins.

Editorial note, this article was assembled without live web research (Grok unavailable in this generation pass). Evergreen sources are cited above; numerical claims are pulled from our own database snapshot as of 2026-05-17.

Insiders Trades backtest cohort

Our analysis of the UK market under the BUY cohort reveals a noteworthy absence of priced trades, resulting in a mean 90-day return and win rate that are not applicable. In contrast, when examining the global universe, which encompasses 227,594 BUY filings across 17 markets, we observe an aggregate mean 90-day return of -1.70% and an annualised Sharpe ratio of -0.08. These figures suggest that, despite the regulatory framework established by Article 19 of the EU Market Abuse Regulation, the effectiveness of trading strategies in this context remains questionable. The lack of positive returns and the negative Sharpe ratio indicate potential challenges in achieving market efficiency and profitability in the current environment. It is essential to note that the sample size for UK trades is insufficient, and the time horizon of 90 days may not capture longer-term market dynamics.

Last reviewed · 2026-05-18 · By Simon Azoulay · Sources, SEC EDGAR, AMF BDIF, and 28 other regulators.